Prevalence of genetic mutations that predispose to thrombophilia in a Greek Cypriot population
K Angelopoulou1, A Nicolaides, C Constantinou Deltas
1Cyprus Institute of Neurology and Genetics, Department of Molecular Genetics, Nicosia.
Insights
This study found a high prevalence of thrombogenic mutations, including factor V Leiden and MTHFR mutations, in the Greek-Cypriot population. These genetic predispositions to blood clots warrant consideration for screening, especially before surgery or pregnancy.
Area of Science:
- Genetics
- Hematology
- Molecular Biology
Background:
- Hereditary disorders affecting anticoagulation are known risk factors for venous thromboembolism.
- Thrombogenic mutations like factor V Leiden, prothrombin G20210A, and MTHFR C677T are linked to cardiovascular conditions.
Purpose of the Study:
- To determine the prevalence of three key thrombogenic mutations in an unrelated Greek-Cypriot population.
- To assess the frequency of factor V Leiden (G1691), prothrombin (G20210A), and MTHFR (C677T) mutations.
Main Methods:
- Screening of 90 unrelated Greek-Cypriot individuals.
- Genotyping for specific thrombogenic mutations: factor V Leiden, prothrombin G20210A, and MTHFR C677T.
Main Results:
- Factor V Leiden mutation: 12.2% heterozygous, 1.1% homozygous.
- Prothrombin G20210A mutation: 7.8% heterozygous.
- MTHFR C677T mutation: 44.4% heterozygous, 17.8% homozygous.
Conclusions:
- Greek-Cypriots exhibit an elevated frequency of thrombogenic mutations.
- Screening for these mutations is recommended, particularly for individuals planning surgery or pregnancy.
- This is the first study on thrombophilia risk factor mutation frequency in Cyprus.
Abstract:
Several hereditary disorders, particularly those affecting the physiological anticoagulation systems, have been well established as risk factors for venous thromboembolism. In the present study, we investigated the prevalence of the following thrombogenic mutations in a Greek-Cypriot population: the G1691 factor V Leiden mutation, the G20210A mutation in the prothrombin gene, and the C677T mutation in the methylenetetrahydrofolate reductase (MTHFR). All three variants have been documented to be significant risk factors for various cardiovascular conditions. Ninety unrelated subjects were screened. For the Leiden mutation, 11 subjects (12.2%) were heterozygous and one (1.1%) was homozygous. Seven subjects (7.8%) were heterozygous for the G20210A variant in prothrombin; no homozygotes were identified. The C677T mutation in MTHFR was found in 40 individuals in the heterozygous state (44.4%), and in 16 individuals in the homozygous state (17.8%). These data demonstrate that Greek-Cypriots have an increased frequency of thrombogenic mutations, and suggest that screening for these mutations should be seriously considered, especially when surgery or pregnancy is planned. This is the first study for the frequency of mutations in risk factors that predispose to thrombophilia on the island of Cyprus.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Principles of Pharmacogenetics: Types of Genetic Variants
Anticoagulant Drugs: Low-Molecular-Weight Heparins


